Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Der(16)T(1-16) is a nonrandom secondary chromosome aberration in many types of human neoplasia, including myxoid liposarcoma, rhabdomyosarcoma and Philadelphia-chromosome-positive acute lymphoblastic-leukemia.
Mrozek K, Arthur D, Karakousis C, Koduru P, Lebeau M, Pettenati M, Tantravahi R, Mrozek E, Perezmesa C, Rao U, Frankel S, Davey F, Bloomfield C. Mrozek K, et al. Among authors: mrozek e. Int J Oncol. 1995 Mar;6(3):531-8. doi: 10.3892/ijo.6.3.531. Int J Oncol. 1995. PMID: 21556567
Trisomy of chromosome 12 in a case of thecoma of the ovary.
Mrózek K, Nedoszytko B, Babińska M, Mrózek E, Hrabowska M, Emerich J, Limon J. Mrózek K, et al. Among authors: mrozek e. Gynecol Oncol. 1990 Mar;36(3):413-6. doi: 10.1016/0090-8258(90)90154-d. Gynecol Oncol. 1990. PMID: 2156766
[Cytogenetic studies of families with reproductive failure].
Mrózek K, Mrózek E, Nedoszytko B, Babińska M, Gościniak W, Mielnik J, Limon J. Mrózek K, et al. Among authors: mrozek e. Wiad Lek. 1989 Oct 1-Nov 1;42(19-21):1014-8. Wiad Lek. 1989. PMID: 2638049 Polish.
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.
Prasath V, Boutrid H, Wesolowski R, Abdel-Rasoul M, Timmers C, Lustberg M, Layman RM, Macrae E, Mrozek E, Shapiro C, Glover K, Vater M, Budd GT, Harris L, Isaacs C, Dees C, Perou CM, Johnson GL, Poklepovic A, Chen H, Villalona-Calero M, Carson W, Stover DG, Ramaswamy B. Prasath V, et al. Among authors: mrozek e. Breast Cancer Res Treat. 2024 Dec 7. doi: 10.1007/s10549-024-07551-z. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39644403
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.
Quiroga D, Wesolowski R, Zelinskas S, Pinette A, Benner B, Schwarz E, Savardekar H, Johnson C, Stiff A, Yu L, Macrae E, Lustberg M, Mrozek E, Ramaswamy B, Carson WE 3rd. Quiroga D, et al. Among authors: mrozek e. Cancer Control. 2024 Jan-Dec;31:10732748241250189. doi: 10.1177/10732748241250189. Cancer Control. 2024. PMID: 38797949 Free PMC article. Clinical Trial.
51 results